Enasidenib Mesylate vs Ipilimumab

## Enasidenib Mesylate vs Ipilimumab: Overview

This comparison examines the pharmacological differences between **Enasidenib Mesylate** and **Ipilimumab**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

## Pharmacokinetics

**Half-life**: Enasidenib Mesylate — N/A; Ipilimumab — 14.7 days.

## Chemical Properties

**Type**: Enasidenib Mesylate — Small molecule; Ipilimumab — Antibody.